Jaguar Health (JAGX) Stock Overview
A commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
JAGX Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Jaguar Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.55 |
| 52 Week High | US$161.70 |
| 52 Week Low | US$2.53 |
| Beta | 0.026 |
| 1 Month Change | -54.92% |
| 3 Month Change | -88.58% |
| 1 Year Change | -97.69% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Narrative Update • May 17
JAGX: Nasdaq Delisting Risk Will Set Up Future Upside Repricing
Analysts have reset Jaguar Health's fair value estimate from $7.50 to $262.50, reflecting a revised view on the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Nasdaq staff issued a delisting notice on May 1, 2026, citing Jaguar Health's publicly held shares of common stock of approximately 401,226 after the 1 for 35 reverse stock split, which is below the 500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(a)(4) (Nasdaq notice).Narrative Update • Apr 25
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Analysts have adjusted their price target for Jaguar Health to $7.50, reflecting updated views on the company’s profit margin profile and long term P/E expectations, while keeping fair value and growth assumptions broadly in line with prior estimates. What's in the News Jaguar Health filed its 10-K on April 7, 2026, with auditor RBSM LLP issuing an unqualified opinion.Recent updates
Narrative Update • May 17
JAGX: Nasdaq Delisting Risk Will Set Up Future Upside Repricing
Analysts have reset Jaguar Health's fair value estimate from $7.50 to $262.50, reflecting a revised view on the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Nasdaq staff issued a delisting notice on May 1, 2026, citing Jaguar Health's publicly held shares of common stock of approximately 401,226 after the 1 for 35 reverse stock split, which is below the 500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(a)(4) (Nasdaq notice).Narrative Update • Apr 25
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Analysts have adjusted their price target for Jaguar Health to $7.50, reflecting updated views on the company’s profit margin profile and long term P/E expectations, while keeping fair value and growth assumptions broadly in line with prior estimates. What's in the News Jaguar Health filed its 10-K on April 7, 2026, with auditor RBSM LLP issuing an unqualified opinion.Narrative Update • Apr 10
JAGX: Nasdaq Listing Risk Will Drive Future Upside Repricing Potential
Analysts have adjusted their price target for Jaguar Health to reflect updated assumptions for slower revenue growth, largely unchanged profit margins, and a substantially higher forward P/E multiple. What's in the News Jaguar Health reported that it will be unable to file its next 10-K by the SEC deadline, indicating a delay in required financial reporting (SEC filing announcement).Narrative Update • Mar 27
JAGX: Nasdaq Listing Risk Will Trigger Future Upside Repricing Potential
Analysts now place Jaguar Health's price target at $7.50, consistent with the prior $7.50 view. They cite broadly unchanged fair value, discount rate and revenue growth assumptions, alongside a slightly lower profit margin outlook and a modestly higher future P/E expectation.Narrative Update • Mar 12
JAGX: Nasdaq Listing Risk Will Set Up Potential Upside Repricing
Analysts maintained their $7.50 price target for Jaguar Health, citing a higher discount rate and slightly lower assumed profit margins, partly offset by a higher future P/E assumption, as the key factors in their updated model. What's in the News On March 5, 2026, Nasdaq notified Jaguar Health that its common stock had closed below the minimum US$1.00 bid price for 30 consecutive business days, leaving the company out of compliance with Nasdaq Listing Rule 5550(a)(2) (Key Developments).Narrative Update • Feb 25
JAGX: Short Term Funding Will Support Improved Profitability Expectations
Analysts have reset their price target for Jaguar Health from $28 to $7.50. They now apply a lower discount rate, more moderate revenue growth expectations, slightly tighter profit margin assumptions, and a higher future P/E multiple in their updated model.
Narrative Update • Feb 09
JAGX: Recent Debt Financing Will Support Upside Potential
Analysts have slightly adjusted their fair value estimate for Jaguar Health to US$35.00. This reflects small tweaks to discount rate, revenue growth and future P/E assumptions rather than a major shift in their overall thesis.Narrative Update • Jan 25
JAGX: Near Term Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have adjusted their price target for Jaguar Health to US$35.00, reflecting updated views on fair value, discount rate, growth assumptions and future P/E that they consider better aligned with the stock's current risk and return profile. What's in the News Jaguar Health entered into a securities purchase agreement on January 6, 2026, for unsecured promissory notes with an aggregate principal amount of US$350,000, carrying 6% annual interest and maturing one month after issuance (Key Developments).Narrative Update • Jan 11
JAGX: Upcoming Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have slightly adjusted their fair value target for Jaguar Health to US$35.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the headline price target level unchanged. What's in the News On November 24, 2025, Jaguar Health, Inc.Narrative Update • Dec 26
JAGX: Future Private Placements Will Support Balance Sheet And Upside Potential
Analysts have raised their price target on Jaguar Health to 35.00 dollars, reflecting slightly higher long term revenue growth assumptions and a modestly higher discount rate. Together these factors keep fair value effectively unchanged while acknowledging incremental upside potential.Narrative Update • Dec 12
JAGX: Future Capital Raises Will Strengthen Balance Sheet And Support Upside Potential
Analysts have modestly reduced their price target on Jaguar Health to reflect a lower fair value estimate of 35 dollars from 40 dollars, even as they factor in stronger revenue growth and a higher future price to earnings multiple, partially offset by slightly softer profit margin assumptions and a lower discount rate. What's in the News Jaguar Health closed a private placement transaction on November 24, 2025, further advancing its ongoing capital raising efforts (Key Developments).Analysis Article • Aug 29
Slammed 27% Jaguar Health, Inc. (NASDAQ:JAGX) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 27% in the...Analysis Article • Jul 02
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 43% Hiding
The Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has fared very poorly over the last month, falling by a substantial...
New Narrative • Apr 18
FDA And EMA Fast-Track Approvals Will Advance Orphan Treatments
New collaborations and regulatory approvals could quicken market entry, increase revenue, and improve earnings through enhanced access to global markets for orphan disease treatments.Analysis Article • Feb 05
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 30%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 30% after a relatively good period...Analysis Article • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders won't be pleased to see that the share price has had a very rough...Analysis Article • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 27% after a relatively good period...Analysis Article • Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 55% in the...Analysis Article • May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have retraced a considerable 49% in the last month, reversing a fair amount...Analysis Article • Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders are no doubt pleased to see that the share price has bounced 55% in...Analysis Article • Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Unfortunately for some shareholders, the Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has dived 39% in the last...Analysis Article • Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 32% in the...Analysis Article • Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Oct 17
Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Jaguar Health's (NASDAQ:JAGX) Italian firm Napo Therapeutics said on Monday the European Commission had decided to grant Orphan Drug Designation for crofelemer to treat microvillus inclusion disease, a rare congenital diarrheal disorder. (JAGX) has risen ~19%. Microvillus inclusion disease is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and even death from severe secretory diarrheaShareholder Returns
| JAGX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 22.0% | 3.3% | 1.8% |
| 1Y | -97.7% | 44.6% | 28.4% |
Return vs Industry: JAGX underperformed the US Pharmaceuticals industry which returned 44.6% over the past year.
Return vs Market: JAGX underperformed the US Market which returned 28.4% over the past year.
Price Volatility
| JAGX volatility | |
|---|---|
| JAGX Average Weekly Movement | 23.4% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: JAGX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: JAGX's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 47 | Lisa Conte | jaguar.health |
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
Jaguar Health, Inc. Fundamentals Summary
| JAGX fundamental statistics | |
|---|---|
| Market cap | US$1.98m |
| Earnings (TTM) | -US$34.26m |
| Revenue (TTM) | US$29.57m |
0.1x
P/S Ratio-0.1x
P/E RatioIs JAGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JAGX income statement (TTM) | |
|---|---|
| Revenue | US$29.57m |
| Cost of Revenue | US$4.42m |
| Gross Profit | US$25.15m |
| Other Expenses | US$59.41m |
| Earnings | -US$34.26m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -56.81 |
| Gross Margin | 85.06% |
| Net Profit Margin | -115.87% |
| Debt/Equity Ratio | -527.7% |
How did JAGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/29 21:33 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jaguar Health, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Christian Orquera | First Berlin Equity Research GmbH |